Leon (lianyong) Chen

Biography

Dr. Chen is Founder and Managing Partner of Frontline BioVentures, boasting over 19 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1000 Talent Plan, and an adviser to BioBAY of Suzhou Industrial Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). While serving as a management consultant in the past, he worked at McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and was a key member of the discovery team of Zytia / Vytorin - a multi-billion dollar drug. Dr. Chen was a Post-Doc at MIT, Ph.D. (with top honor) from the University of Louvain, Louvain-La-Neuve, B.S. from Peking University. He holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.

Research Interest

Business, Management, Toxicology, Pharmacology